E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Autor: Bajrami I; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Marlow R; The Breast Cancer Now Research Unit, King's College London, London, United Kingdom., van de Ven M; Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Brough R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Pemberton HN; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Frankum J; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Song F; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Rafiq R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Konde A; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Krastev DB; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Menon M; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Campbell J; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Gulati A; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Kumar R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Pettitt SJ; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Gurden MD; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Cardenosa ML; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Biomedical Research Institute INCLIVA, Hospital Clinico Universitario Valencia, University of Valencia, Spain., Chong I; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Gazinska P; The Breast Cancer Now Research Unit, King's College London, London, United Kingdom., Wallberg F; FACS Core Facility, The Institute of Cancer Research, London, United Kingdom., Sawyer EJ; Division of Cancer Studies, Guy's Hospital, King's College London, London, United Kingdom., Martin LA; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Dowsett M; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Linardopoulos S; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Natrajan R; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom., Ryan CJ; Systems Biology Ireland, University College Dublin, Dublin, Ireland., Derksen PWB; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jonkers J; Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Tutt ANJ; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; The Breast Cancer Now Research Unit, King's College London, London, United Kingdom., Ashworth A; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. Chris.Lord@icr.ac.uk alan.ashworth@ucsf.edu., Lord CJ; The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Chris.Lord@icr.ac.uk alan.ashworth@ucsf.edu.; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.

Publikováno v: Cancer discovery [Cancer Discov] 2018 Apr; Vol. 8 (4), pp. 498-515.

Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.

Autor: Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Mak GWY; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Gurden MD; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK., Xavier CPR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., O'Fee L; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Schmitt J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., vanMontfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.; Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.

Publikováno v: British journal of cancer [Br J Cancer] 2017 Apr 25; Vol. 116 (9), pp. 1166-1176. Date of Electronic Publication: 2017 Mar 23.

Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.

Autor: Gurden MD; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom., Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Division of Structural Biology, The Institute of Cancer Research, London, United Kingdom., Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Cheung KM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., McAndrew C; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Wood A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Schmitt J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Boxall K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Mak G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Workman P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom., Van Montfort RL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Division of Structural Biology, The Institute of Cancer Research, London, United Kingdom., Linardopoulos S; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom. Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Spiros.Linardopoulos@icr.ac.uk.

Publikováno v: Cancer research [Cancer Res] 2015 Aug 15; Vol. 75 (16), pp. 3340-54. Date of Electronic Publication: 2015 Jul 22.

Cdc20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F.

Autor: Gurden MD; Faculty of Life Sciences, Michael Smith Building, University of Manchester, Manchester M13 9PT, UK., Holland AJ, van Zon W, Tighe A, Vergnolle MA, Andres DA, Spielmann HP, Malumbres M, Wolthuis RM, Cleveland DW, Taylor SS

Publikováno v: Journal of cell science [J Cell Sci] 2010 Feb 01; Vol. 123 (Pt 3), pp. 321-30. Date of Electronic Publication: 2010 Jan 05.